As part of its disease interception strategy to halt progression of type 1 diabetes (T1D) before the disease manifests, the Disease Interception Accelerator (DIA) began a research alignment with JDRF, a leading research and advocacy organization funding T1D research. The goal of the alignment is to inform and accelerate targeted and science-based solutions for T1D.
Careers
We’re always seeking talented people who share our vision. Click here to explore opportunities in a variety of disciplines across the globe.
See More >
See More >
Leadership Blogs
Get to know our leaders. Read their unique perspectives on how they are working to change the trajectory of health.
See More >
See More >
We’re committed to showing the heart of the caregiver’s experience and providing the kind of support and information that will make a difference.
See More >
See More >
Patient Engagement
Janssen partners directly with patients and caregivers as we develop medicines, improve clinical trials, and create educational materials and support programs.
See More >
See More >
Research & Development
Our research pipeline is rich with transformational science reflecting our unique approach to innovation.
See More >
See More >
Using data science and digital health to reimagine the discovery and development of medicines to advance our mission of bringing transformative therapies to patients.
See More >
See More >
Collaborating in more than 150 markets.
By clicking on a link below, you may enter a different part of this website, or a website outside of Janssen.com.
These sections or websites are governed by their own Legal and Privacy Policies.
Global
Asia Pacific
Europe, Middle East & Africa (EMEA)
Latin America
Home › JDRF partnership
JDRF partnership
Janssen Sets a Course to Intercept Type 1 Diabetes Together with JDRF